This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Dendritic Cell Vaccination in Patients With Advanced Colorectal Cancer

This study has been completed.
Information provided by:
University Hospital, Gentofte, Copenhagen Identifier:
First received: April 3, 2006
Last updated: February 17, 2009
Last verified: February 2009

Dendritic cells loaded with tumor antigens induce cytotoxic T-cells which have been proved capable of killing both melanoma and breast cancer cells. Melanoma and colorectal cancer cells express some common antigens. Hence it is possible to use melanoma lysate to load the dendritic cells with tumor antigens similar to the antigens expressed by the patients' colorectal cancer cells.

The patient receives 10 vaccinations with 14 days between each. The parameters for effect are changes in tumor/metastasis size measured with computed tomography (CT), decrease in serum concentration of carcinoembryonic antigen (CEA), performance status measured by the World Health Organization (WHO) criteria, and Quality of Life.

Condition Intervention Phase
Colorectal Neoplasms Biological: MelCancerVac Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: Vaccination With Autologous Dendritic Cells Pulsed With Allogenous Melanoma Lysate (MelCancerVac) for Treatment of Patients With Advanced Colorectal Cancer

Resource links provided by NLM:

Further study details as provided by University Hospital, Gentofte, Copenhagen:

Estimated Enrollment: 40
Study Start Date: November 2004
Study Completion Date: September 2007

Ages Eligible for Study:   25 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Verified cancer of colon or rectum
  • No chemo- or radiation therapy in 6 weeks
  • Performance status 0, 1, or 2 (WHO criteria)
  • Adequate function of the kidneys, liver, lungs, and heart
  • Adequate function of the hematopoietic system and the coagulation system
  • Negative pregnancy test and adequate birth control for fertile women

Exclusion Criteria:

  • Pregnancy
  • Uncontrolled infection
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00311272

Surgical Department, University Hospital Gentofte
Hellerup, Denmark, 2900
Sponsors and Collaborators
University Hospital, Gentofte, Copenhagen
Principal Investigator: Anders Fischer, MD University Hospital Gentofte
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00311272     History of Changes
Other Study ID Numbers: 2612-1970
Study First Received: April 3, 2006
Last Updated: February 17, 2009

Keywords provided by University Hospital, Gentofte, Copenhagen:
dendritic cells
antigens, neoplasm

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases processed this record on September 21, 2017